VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage

Eitemau Tebyg

• Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
  gan: Catalina Abad, et al.
  Cyhoeddwyd: (2017-08-01)
• Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
  gan: Abad, Catalina, et al.
  Cyhoeddwyd: (2017)
• VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses
  gan: Tan, Yossan-Var, et al.
  Cyhoeddwyd: (2014)
• Systemic administration of orexin A ameliorates established experimental autoimmune encephalomyelitis by diminishing neuroinflammation
  gan: Becquet, Laurine, et al.
  Cyhoeddwyd: (2019)
• Pituitary Adenylate Cyclase Activating Peptide Deficient Mice Exhibit Impaired Thymic and Extrathymic Regulatory T Cell Proliferation during EAE
  gan: Tan, Yossan-Var, et al.
  Cyhoeddwyd: (2013)